Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 683Carcinoma, Renal Cell 225Urinary Bladder Neoplasms 195Carcinoma, Transitional Cell 111Breast Neoplasms 96Kidney Neoplasms 89Carcinoma, Non-Small-Cell Lung 82Neoplasms 81Melanoma 78Ovarian Neoplasms 77Colorectal Neoplasms 68Neoplasm Metastasis 66Non-Muscle Invasive Bladder Neoplasms 56Lung Neoplasms 53Pancreatic Neoplasms 46Sarcoma 45Stomach Neoplasms 42Endometrial Neoplasms 41Uterine Cervical Neoplasms 39Wilms Tumor 33Adenocarcinoma 33Esophageal Neoplasms 31Carcinoma, Hepatocellular 31Squamous Cell Carcinoma of Head and Neck 30Triple Negative Breast Neoplasms 29Head and Neck Neoplasms 27Testicular Neoplasms 24Metastatic Castration-resistant Prostate Cancer 24Neuroblastoma 23Colonic Neoplasms 23

Interventions

enzalutamide 2apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × 90 days × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡